Executive and General Board

Executive Board 2022-2024

EANO President 2022-2024

Susan Short, United Kingdom

Professor Susan Short is Professor of Clinical Oncology and Neuro Oncology in the School of Medicine at the University of Leeds and Consultant Clinical Oncologist at St James’s University Hospital, Leeds. She is an academic oncologist with a research interest in the treatment of adult brain tumours. This includes clinical research in technical radiotherapy developments as well as drug-radiotherapy combinations in early phase clinical studies. She is PI for a portfolio of local and national clinical studies. Her recent laboratory work has included investigation of oncolytic viruses as immune stimulants and adjuvants in gliomas, targeting micro-RNA biology in gliomas and identifying novel approaches to preventing DNA repair following cytotoxic treatments. She has many years of experience in developing and leading major national clinical research groups including as Chair of the UK NCRI Brain Tumour Clinical Study Group, UK NCRI CTRad pre-clinical workstream and is president-elect of the British Neuro Oncology Society. She has been involved in collaborative network activity in EU FP7 (INSERT) as well as national radiotherapy research (CRUK ART-NET and RAD-NET) and national glioma consortia (BRAIN-MATRIX). She currently leads an international consortium addressing application of liquid biomarkers in glioma (BRAIN-LBC).

Susan Short, United Kingdom
EANO Past-President 2020-2022

Matthias Preusser, Vienna, Austria

Matthias Preusser is a full Professor of Medical Oncology and Head of the Division of Oncology at the Medical University of Vienna. His research focuses on biomarkers and therapy in brain tumours. Recent works focus on the characterization of inflammatory infiltrates and immune checkpoint molecules in various types of brain tumours, the biology of brain metastases and identification of novel treatment options for meningiomas. Dr. Preusser is Chair-elect of the European Organisation for Research and Treatment of Cancer Brain Tumour Group and is leading or actively involved in several international clinical trials in Neuro-oncology.

Matthias Preusser, Vienna, Austria
EANO Treasurer

Roberta Rudà, Turin, Italy

Dr. Roberta Rudà is a Neurologist who has been involved in neuro-oncology for up to 20 years.

Since 2011 she is Head of the Outpatient Service and Multidisciplinary Brain Tumor Board, City of Health and Science Hospital/University of Turin. She is also the Coordinator of the Neuro-Oncology Network of the  Regione Piemonte and Valle D’Aosta.

Dr. Roberta Rudà is Professor of Neuro-Oncology in the Residency Programs of Neurosurgery and Diagnostic Imaging/Radiotherapy of the University of Turin.

The major research areas are represented by primary brain tumors with particular interest in lower grade gliomas, epilepsy, and primary CNS lymphomas. Translational research, functional neuroimaging and neurological complications of cancers (in particular neoplastic meningitis and brain metastases) have been a focus of interest as well. In this regard Dr. Rudà is Principal Investigator in several international clinical trials.

Dr. Rudà is Member of the Editorial Board of Neuro-Oncology, Neuro-Oncology Practice, Journal of Neurosurgical Sciences and World Federation of Neuro-Oncology Magazine, and Reviewer for J. Neuro-Oncology, Lancet Oncology, J. Neurology and Epilepsia.

Dr. Rudà has been a Member of the Scientific Committee of EANO since 2014, and Member of the EANO Task Forces for Guidelines in PCNSL, Ependymomas, Leptomeningeal Metastases, Brain Metastases and Palliative/Supportive Care. She is Member of the RANO Groups on Leptomeningeal Metastases and Epilepsy in Brain Tumors, and of the Brain Tumor Group of EORTC.

She is Secretary of the Italian Association of Neuro-Oncology (AINO) since 2013 and she has been the chair of the Local Organizing Committee of the EANO Congress in Turin, 2014.

Roberta Rudà, Turin, Italy
Executive Board Member 2022-2024

Anna Berghoff, Vienna, Austria

Anna Sophie Berghoff is a medical oncologist at the Medical University of Vienna. Here, she head the CNS tumor program including the subversion of International clinical trials as well as translational research projects. Her particular research focus are cancer- immune system interaction in the context of primary an secondary brain tumors.

Anna Berghoff, Vienna, Austria
EANO Executive Board Member 2022-2024, EANO Meeting President 2024

Anthony Chalmers, Glasgow, United Kingdom

Anthony Chalmers is Chair of Clinical Oncology at the University of Glasgow. His clinical practice at the Beatson West of Scotland Cancer Centre is devoted to the treatment of patients with brain tumours, and he runs the Translational Radiation Biology laboratory in the Institute for Cancer Sciences. His main research interest is in improving outcomes for patients with glioblastoma by combining radiotherapy with targeted drug therapies, but his research interests in radiotherapy-drug combinations extend across tumour sites including lung cancer and mesothelioma. He is Chief Investigator for a portfolio of early phase clinical trials evaluating the oral PARP inhibitor olaparib in combination with radiotherapy and/or chemotherapy in treatment of glioblastoma, and also leads the randomised phase II SYSTEMS-2 trial of radiotherapy dose escalation in mesothelioma. He is Chair of the UK’s Clinical and Translational Radiotherapy Research Working Group (CTRad) and is a scientific theme lead for the Radiotherapy-Drug Combinations Consortium (RaDCom), a joint initiative between Cancer Research UK and the UK National Cancer Research Institute. Previously a member of the Scientific Committee of the European Association for Neuro-Oncology (EANO), he sits on the Radiobiology Committee of the European Society for Therapeutic Radiation Oncology (ESTRO) and is Chair of the Scottish Radiotherapy Research Forum (ScoRRF).

Anthony Chalmers, Glasgow, United Kingdom
EANO Executive Board Member 2022-2024

Christian Mawrin, Germany

Christian Mawrin is full professor of neuropathology and head of the department of neuropathology at the Otto-von-Guericke University in Magdeburg / Germany. His main research interest is meningioma biology with a focus on translational research combining human tissue analysis with in vitro and in vivo model systems. Recent works center around modeling of recurrent somatic mutations in meningiomas to study their biological function and potential treatment options. Christian Mawrin is secretary general of the german neuropathological society (DGNN) and editor-in chief of Clinical Neuropathology.

Christian Mawrin, Germany
EANO Executive Board Member 2022-2024

Emilie Le Rhun

Emilie Le Rhun joined the Department of Neurosurgery, University Hospital and University of Zurich in June 2020. Before she has been Senior Neuro-Oncologist at the Department of Neurosurgery at the University Hospital Lille, France, since 2007 and at the Cancer Center Oscar Lambret since 2005. She was a member of the EANO Scientific Committee from 2016 to 2020 and is a member of the EANO Guidelines Committee from May 2019, also Member of EANO Guideline Task Force on Glioma; Brain Metastases; Meningioma, Palliative Care. She has been coordinatating the Women in Neuro-Oncology task force /Disparity Committee since its creation in 2019 until 2022. She is also member of the Steering Committee of the EORTC Brain Tumor Group, has been elected Secretary of the EORTC Brain Tumor group in 2020 and leads the EORTC Brain Tumor Group CNS Metastasis Committee. She also serves on various task forces of ESMO and RANO. Her main research interests are brain and leptomeningeal metastasis, including the role of liquid biopsies. She served as the Chairperson of the joint EANO ESMO guideline taskforces on leptomeningeal and brain metastases.

Emilie Le Rhun
EANO Executive Board Member 2022-2024

Evangelia Razis, Athens, Greece

Dr. Razis studied medicine at Northwestern University, Chicago, IL. She completed a three year medical residency at Beth Israel Medical Center, a six year Honors Program and a three year Oncology Fellowship at New York Medical College/Westchester County Medical Center. She then worked as an Instructor of Medicine in New York Medical College. Upon returning to Greece, she started working as an attending at Hygeia hospital while completing a Ph.D. in Medicine. She is currently appointed as Director in the 3rd Oncology department in Athens, Greece at “Hygeia” Hospital. In the Spring of 2016, Dr. Razis led her practice to the first ever Quality certification by ASCO for an international practice.

Dr. Razis has a strong interest in education, giving several lectures a year and teaching doctors who are in the process of specialization. She has worked voluntarily in the Sudan, in Sri Lanka, in the Honduras, in Zimbabwe, in Rwanda and in Kefalonia, Greece. Her specific interests include Breast Cancer and Neuro-oncology. She actively participates in a number of Medical Associations and cooperative groups, including ASCO, ESMO, EANO, SNO, HeCOG, National Cancer Institute, the Breast International Group, the EORTC Breast Cancer Group, the EORTC Brain Tumor Group, where she is appointed to the Quality assurance subcommittee, and Brain Tumor Funders’ Collaborative Consortium. She has published over 100 papers, has presented several abstracts-posters in international congresses and meetings and has worked on 22 chapters and courses.

Evangelia Razis, Athens, Greece
EANO Executive Board Member 2022-2024

Giuseppe Minniti, Italy

Professor of Radiation Oncology and Chair of Academic Unit of Radiation Oncology, Department of Medicine, Surgery and Neuroscience, University of Siena, Si, Italy. Clinical Associate Professor of Radiation Oncology, University of Pittsburgh, PA, USA. Professor Giuseppe Minniti is a radiation oncologist with a specialist research interest in treating adults with primary brain and spine tumors. He completed his medical school training, radiation oncology residency training, and PhD course at University of Rome Sapienza and his fellowship/postdoctoral training in radiation oncology and neuro-oncology at Royal Marsden Hospital NHS Foundation Trust London. Major research interests include optimization of radiation techniques and chemotherapyfor patients with primary and metastatic brain tumors. Professor Minniti serves as a member of the European Association for Neuro-Oncology (EANO), EORTC Brain Tumor Group (treasurer and Chair of Radiotherapy committee), Italian Association of Neuro-Oncology (AINO) and is currently coordinator of CNS tumors of European Society for Medical Oncology (ESMO) Faculty Group. .

Giuseppe Minniti, Italy
EANO Executive Board Member 2022-2024

Lena Rosenlund, Sweden

Lena Rosenlund has a Master of Science in Nursing. Her engagement for patient and caregivers affected by brain tumors started 1997 as a clinical nurse at a neurosurgical ward at the Karolinska university hospital, Stockholm, Sweden. In 2007, she was part of a project to develop a new nursing role in Sweden, contact nurses. As a contact nurse, she was part of the neuro-oncology team and supported patients affected by malignant brain tumor and their caregivers, from the time of diagnosis to death regardless of disease status or clinic involved. Since 2012, she works at the Regional Cancer Centre in Stockholm but are currently about to finish her PhD studies at The Institute of Health and Caring Sciences at Sahlgrenska Academy, Gothenburg University. The focus on her thesis are person-centred care and patient-reported measures. Her key interest in research is support to patient and caregivers affected by CNS tumors, psychometrics and metrology in the health sciences, patient involvement and the use of patient-reported measures in clinical practice, improvement work and research. She is an active member of the board of the Swedish national quality registry for brain tumors and implemented patient-reported measures in the registry 2016. She is also part of a national working group for a new real-time registry and to generate online output reports from the national quality to register to reporting clinics. She has joined all the EANO meetings since 2008 and are a member of the EANO Nurses and Allied healthcare professionals since 2021. Lena wishes to contribute to research in neuro-oncology nursing and patient-reported measures and to support other nurses/AHPs to do research, improvement work and network with colleagues around Europe.

Lena Rosenlund, Sweden

General Board 2022-2024

EANO Co-Opted Board Member, Chair Nurse and Allied Health Professionals Committee

Karin Piil, Copenhagen, Denmark

Karin Piil has been working within neuro-oncology since 1994; as a head nurse at the Department of Neurosurgical and currently as a senior researcher at the Department of Oncology at Rigshospitalet, Copenhagen, Denmark.

She holds an international Master of Health Science, Nursing from Deakin University, Melbourne Australia and a Ph.D. on patients with high-grade glioma and the caregivers from the Faculty of Health and Medical Sciences, University of Copenhagen.

Her research has focused on patients’ and relatives´ perspectives on the high-grade glioma trajectory and coping strategies, for example related to the notion on hope and how families and networks can be involved. Current research is inspired from Linné university at Kalmar, Sweden and explores whether systematic and nurse-led family/network conversations can enhance the well-being and social support for the patient.

Karin Piil has a key interest on research on the patient and relative perspectives on the neuro-oncological disease- and treatment course, symptoms such as cognitive challenges, quality of life, family dynamics, bereaved caregivers, patients’ and relatives’ involvement in research processes and decision-making processes among patients with recurrence of malignant brain tumors.

Karin Piil wish to contribute to an even stronger development of an European neuro-oncological research agenda that brings together a multi professional perspective.

Karin Piil, Copenhagen, Denmark
EANO Co-Opted Board Member, Chair Scientific Committee

Manuel Valiente, Madrid, Spain

Manuel Valiente is Head of the Brain Metastasis Group at CNIO (Madrid) where he investigates the biology of brain metastasis in order to challenge this unmet clinical need. Specifically, his laboratory studies novel brain metastasis mediators, characterizes the metastasis-associated microenvironment, designs better experimental models and explores novel methods to target brain metastasis. All these aims consider the brain environment as a critical component to understand the biology of this progression of cancer. Dr. Valiente has co-founded the first National Network of Brain Metastasis (RENACER) in Spain, which is allowing his team to translate laboratory findings to clinical studies faster. In addition, he has established a large network of international clinical collaborators for the same purpose. His contributions to brain metastasis research have been recognized with the ASPIRE Award, ERC CoG, EMBO YIP, CLIP Award, Beug Foundation’s Prize for Metastasis Research, Bristol-Myers Squibb-MRA Young Investigator Award among others. He is the Chair of the Scientific Committee of the European Association of Neuro-Oncology (EANO), and Board Member of the Metastasis Research Society (MRS) and ESMO faculty member (CNS Tumours faculty group).

Manuel Valiente, Madrid, Spain
EANO Co-opted Board member, EANO Meeting President 2023

Martin van den Bent, Rotterdam, Netherlands

After completing my training as a neurologist I joined in 1992 the Neuro-Oncology Unit of Erasmus MC - Daniel den Hoed Cancer Center in Rotterdam, the Netherlands. This neuro-oncology unit is focused on the treatment of primary brain tumors and on neurological complications of cancer and its treatment. We  integrated in 2013 this unit with the brain tumor specialists of the department of neurosurgery into a Brain Tumor Center at Erasmus MC Cancer Center. I believe in the multidisciplinary approach, and in good clinical evidence as the corner stone of treatment. For those reasons I have been the principle investigator many large international multicenter phase II and III trials on both high and low grade glial tumors. Most of these have been conducted through the EORTC Brain Tumor Group, as this important network allows the conduct of glioma trials that make a difference. I have served between 2003 and 2009 as the chair of this internationally well recognized group, and I am currently member of the EORTC Board. I have had the honor of receiving in 2004 and in 2014 the award for excellence in clinical research by the Society for Neuro-Oncology, and to be the 2015 recipient of the 2015 ECCO Clinical Research Award. Bringing the latest research and clinical developments to patients is important, and for that reason I have established and co-chaired four editions of a bi-annual EORTC-EANO-ESMO educational course on brain tumors. We have several European professional organizations that at least partially focus on brain tumors, these need to collaborate but more importantly: EANO is pre-eminently the multidisciplinary organization for brain tumors and therefore the leading European organization for physicians and scientists devoted to neuro-oncology Recently a European Rare Cancer Network has been proposed, of which I coordinated the glioma part. A key role for EANO is obviously needed here as well.

Martin van den Bent, Rotterdam, Netherlands
Chair EANO Youngsters Committee

Jan-Michael Werner, Cologne, Germany

Jan-Michael Werner, MD, is currently a neurology resident at the University Hospital Cologne, Germany, and research fellow within the Cologne Clinician Scientist Program, supported by the German Research Council (DFG). His research work focuses on multimodal imaging including amino acid PET and advanced MRI as well as immunotherapy in patients with brain tumors.

Jan-Michael Werner, Cologne, Germany